Wall Street brokerages forecast that AC Immune SA (NASDAQ:ACIU) will report earnings of $0.53 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for AC Immune’s earnings, with estimates ranging from ($0.20) to $0.99. AC Immune reported earnings of $0.07 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 657.1%. The firm is scheduled to issue its next earnings report on Tuesday, March 19th.
On average, analysts expect that AC Immune will report full year earnings of ($0.01) per share for the current financial year, with EPS estimates ranging from ($0.81) to $0.40. For the next year, analysts forecast that the business will report earnings of ($0.31) per share, with EPS estimates ranging from ($0.95) to $0.02. Zacks’ EPS calculations are a mean average based on a survey of research analysts that cover AC Immune.
AC Immune (NASDAQ:ACIU) last issued its earnings results on Tuesday, November 13th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.04. The company had revenue of $2.34 million during the quarter, compared to analysts’ expectations of $1.71 million. AC Immune had a negative net margin of 146.09% and a negative return on equity of 24.14%.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ACIU. JPMorgan Chase & Co. acquired a new position in shares of AC Immune during the 3rd quarter worth about $142,000. Janus Henderson Group PLC acquired a new position in shares of AC Immune during the 3rd quarter worth about $13,345,000. Alps Advisors Inc. acquired a new position in shares of AC Immune during the 4th quarter worth about $1,471,000. Belpointe Asset Management LLC acquired a new position in shares of AC Immune during the 3rd quarter worth about $400,000. Finally, Sphera Funds Management LTD. acquired a new position in shares of AC Immune during the 3rd quarter worth about $4,029,000. Institutional investors and hedge funds own 29.30% of the company’s stock.
Shares of AC Immune stock traded down $0.05 on Friday, hitting $3.95. 2,391 shares of the company’s stock traded hands, compared to its average volume of 904,345. AC Immune has a one year low of $3.25 and a one year high of $17.40. The stock has a market capitalization of $258.18 million, a price-to-earnings ratio of -13.24 and a beta of -0.09.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Article: What does RSI mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.